AndrÃ© Baruchel

List of Publications by Year
in descending order

80 papers	5,634 citations	394421 19 h-index	102487 66 g-index
80 all docs	80 docs citations	80 times ranked	8190 citing authors

#	Article	IF	Citations
1	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood, 2022, 139, 1785-1793.	1.4	28
2	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. Blood Cancer Journal, 2022, 12, 14.	6.2	10
3	Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients. Pharmaceuticals, 2022, 15, 375.	3.8	7
4	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia, 2022, 36, 1525-1532.	7.2	27
5	Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Journal of Cancer Research and Clinical Oncology, 2022, , 1.	2.5	1
6	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. Modern Pathology, 2022, 35, 1227-1235.	5.5	5
7	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. Journal of Clinical Oncology, 2022, 40, 10001-10001.	1.6	15
8	IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL. Blood, 2021, 137, 1690-1694.	1.4	8
9	Cranial polyneuropathy as the first manifestation of a severe COVIDâ€19 in a child. Pediatric Blood and Cancer, 2021, 68, e28707.	1.5	12
10	Bone Mineral Density Evolution and Its Determinants in Long-term Survivors of Childhood Acute Leukemia. HemaSphere, 2021, 5, e518.	2.7	2
11	Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia. Frontiers in Oncology, 2021, 11, 637951.	2.8	17
12	Infant Acute Myeloid Leukemia: A Unique Clinical and Biological Entity. Cancers, 2021, 13, 777.	3.7	11
13	Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia, 2021, 35, 3383-3393.	7.2	77
14	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. Journal of Hematology and Oncology, 2021, 14, 74.	17.0	10
15	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. Leukemia, 2021, , .	7.2	2
16	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Advances, 2021, 5, 2901-2908.	5.2	29
17	Therapeutic potential of ruxolitinib and ponatinib in patients with <i>EPOR</i>-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica, 2021, 106, 2763-2767.	3.5	12
18	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24

#	Article	IF	Citations
19	Hypoxia favors chemoresistance in T-ALL through an HIF1Î±-mediated mTORC1 inhibition loop. Blood Advances, 2021, 5, 513-526.	5.2	14
20	Results from an international phase 2 study of the antiâ€CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood Bâ€lineage acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28112.	1.5	16
21	COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE). Bulletin Du Cancer, 2020, 107, 629-632.	1.6	18
22	Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22 â€positive Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, e53-e56.	2.5	15
23	Impact of Two Different Types of Rabbit ATG on Immune Reconstitution and Overall Results after Allogeneic Hematopoetic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Children. Blood, 2020, 136, 24-25.	1.4	0
24	JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators. Blood, 2020, 136, 4-5.	1.4	0
25	ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma. Blood, 2020, 136, 42-42.	1.4	3
26	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia, 2019, 33, 348-357.	7.2	44
27	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1710-1718.	10.7	65
28	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood, 2019, 134, 1351-1355.	1.4	89
29	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1981-1988.	5.2	12
30	Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. HemaSphere, 2019, 3, e203.	2.7	13
31	B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. Frontiers in Oncology, 2019, 9, 1374.	2.8	28
32	Adolescence and Socioeconomic Factors: Key Factors in the Long-Term Impact of Leukemia on Scholastic Performanceâ€"A LEA Study. Journal of Pediatrics, 2019, 205, 168-175.e2.	1.8	7
33	Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 538-548.	2.0	81
34	Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study. Blood, 2019, 134, 5130-5130.	1.4	1
35	Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience. Blood, 2019, 134, 3876-3876.	1.4	9
36	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	27.0	3,680

#	Article	IF	Citations
37	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. HemaSphere, 2018, 2, e31.	2.7	40
38	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 289-300.	1.4	97
39	Maintenance Therapy With Interleukinâ€2 for Childhood AML. HemaSphere, 2018, 2, e159.	2.7	18
40	The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. British Journal of Haematology, 2018, 183, 766-774.	2.5	11
41	Generic formulations of imatinib for treatment of Philadelphia chromosomeâ€“positive leukemia in pediatric patients. Pediatric Blood and Cancer, 2018, 65, e27431.	1.5	11
42	Genetic diversity of the human adenovirus species C DNA polymerase. Antiviral Research, 2018, 156, 1-9.	4.1	3
43	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. Leukemia, 2018, 32, 1878-1882.	7.2	8
44	Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. Blood, 2018, 132, 351-361.	1.4	82
45	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. Blood, 2018, 132, 895-895.	1.4	70
46	Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel. Blood, 2018, 132, 1551-1551.	1.4	12
47	Considerations for tisagenlecleucel dosing rationale.. Journal of Clinical Oncology, 2018, 36, e15056-e15056.	1.6	7
48	Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload. Journal of Visualized Experiments, 2017, , .	0.3	1
49	Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatric Hematology and Oncology, 2017, 34, 425-427.	0.8	14
50	Eosinophilic pneumonias in children: A review of the epidemiology, diagnosis, and treatment. Pediatric Pulmonology, 2016, 51, 203-216.	2.0	31
51	Employment in French young adult survivors of childhood leukemia: an LEA study (for Leucemies de) Tj ETQq1 1 0.784314 rgBT /Over 2016, 10, 1058-1066.	2.9	15
52	Evaluation of a New Device for Simplifying and Standardizing Stool Sample Preparation for Viral Molecular Testing with Limited Hands-On Time. Journal of Clinical Microbiology, 2016, 54, 928-933.	3.9	9
53	Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers. Blood, 2016, 128, 5190-5190.	1.4	1
54	Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score. Blood, 2016, 128, 626-626.	1.4	1

#	Article	IF	Citations
55	The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia. Blood, 2016, 128, 1534-1534.	1.4	1
56	Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program. Haematologica, 2015, 100, e186-e189.	3.5	19
57	Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort). International Journal of Epidemiology, 2015, 44, 49-57.	1.9	60
58	Ovarian reserve after treatment with alkylating agents during childhood. Human Reproduction, 2015, 30, 1437-1446.	0.9	67
59	Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). Blood, 2015, 126, 3723-3723.	1.4	5
60	Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). Blood, 2015, 126, 3734-3734.	1.4	1
61	Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study). Blood, 2015, 126, 1576-1576.	1.4	2
62	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	1.4	0
63	Acceptability of the Fertility Preservation Program and Evaluation of the Gonadal Function in Children after Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 4357-4357.	1.4	0
64	Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. European Journal of Cancer, 2014, 50, 3206-3211.	2.8	79
65	Relevance of a One-Year Maintenance Therapy with Interleukin-2 in the Treatment of Childhood Acute Myeloid Leukemia: Results from the French Multicenter, Phase III, Randomized Controlled Sfce Trial, ELAM02. Blood, 2014, 124, 378-378.	1.4	5
66	The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration. Blood, 2014, 124, 521-521.	1.4	3
67	Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3723-3723.	1.4	0
68	DNA Methylation Profiling of Pediatric AML Reveals That Hypomethylation of MN1 Is Characteristic of Inv(16) AML and a Driver of MN1 Overexpression. Blood, 2014, 124, 867-867.	1.4	0
69	Bromodomain Inhibition By OTX015 Regulates c-MYC and HEXIM1 in a Panel of Human Acute Leukemia Cell Lines. Blood, 2014, 124, 5957-5957.	1.4	0
70	Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry. Blood, 2013, 122, 2613-2613.	1.4	1
71	Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study. Blood, 2013, 122, 4001-4001.	1.4	1
72	Risk Factors For Cerebral Vasculopathy In a Sickle Cell Disease Newborn Cohort. Blood, 2013, 122, 4685-4685.	1.4	0

#	Article	IF	Citations
73	New Design Of Human T-ALL Transplantation In NSG Mice Uncovers The Major Role Of CD31/PECAM1 In The Central Nervous System Infiltration. Blood, 2013, 122, 1436-1436.	1.4	0
74	Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro: Clinical Meaning and Activation Of The NFkB Pathway. Blood, 2013, 122, 2571-2571.	1.4	0
75	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). Blood, 2012, 120, 3561-3561.	1.4	10
76	Early Development of Immunity to CMV Following Hematopoietic-Stem Cell Transplantation Is Associated with Graft-Versus Leukaemia Effect. Blood, 2012, 120, 4214-4214.	1.4	0
77	Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol. Blood, 2012, 120, 135-135.	1.4	0
78	Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.. Blood, 2009, 114, 1628-1628.	1.4	5
79	Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.. Blood, 2006, 108, 1852-1852.	1.4	0
80	Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials. Journal of Clinical Oncology, 2003, 21, 774-780.	1.6	552